Pulmonx Corporation (NASDAQ:LUNG – Get Free Report)’s stock price passed above its 50-day moving average during trading on Wednesday. The stock has a 50-day moving average of $2.02 and traded as high as $2.77. Pulmonx shares last traded at $2.52, with a volume of 7,248,277 shares traded.
Key Headlines Impacting Pulmonx
Here are the key news stories impacting Pulmonx this week:
- Positive Sentiment: Quarterly results exceeded expectations. Pulmonx reported an adjusted loss of $0.19 per share, better than the consensus estimate of a $0.26 loss. Revenue rose 6% year over year to $22.84 million, surpassing expectations of $21.93 million. Pulmonx Q3 Results
- Positive Sentiment: Losses narrowed and operating efficiency improved. GAAP net loss declined to $8.4 million from $14.0 million a year earlier, while operating expenses fell 18% to $24.9 million. Gross margin remained strong at 76%, and U.S. revenue increased 7% to $14.9 million. Pulmonx Revenue and Financial Metrics
- Positive Sentiment: Analysts raised or reaffirmed their bullish views. Stifel Nicolaus raised its price target from $2.50 to $4.00 and assigned a “buy” rating, while Canaccord reiterated its buy rating. These actions provide additional support for the stock’s rally. Stifel Nicolaus Rating Canaccord Rating
- Positive Sentiment: Financial guidance was maintained. Pulmonx kept its 2026 revenue outlook at $90 million to $92 million and ended the quarter with $52.7 million in cash and equivalents, giving investors continued visibility and liquidity. Pulmonx Third-Quarter Results
- Neutral Sentiment: Management will participate in upcoming investor conferences, potentially providing additional visibility into commercial execution and the company’s outlook. Pulmonx Investor Conferences
- Negative Sentiment: Reported insider activity has been unfavorable, with executives recording sales and no purchases during the past six months. Recent institutional filings also showed several large funds reducing their positions, although these data points may not reflect current trading decisions.
Analysts Set New Price Targets
Several equities research analysts have recently commented on the stock. Weiss Ratings raised shares of Pulmonx from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 25th. Canaccord Genuity Group set a $5.00 price objective on shares of Pulmonx in a report on Wednesday. Finally, Stifel Nicolaus raised their price objective on shares of Pulmonx from $2.50 to $4.00 and gave the stock a “buy” rating in a report on Wednesday. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Pulmonx presently has a consensus rating of “Moderate Buy” and an average price target of $7.67.
View Our Latest Stock Analysis on LUNG
Pulmonx Stock Performance
The business’s 50-day moving average price is $2.02 and its 200-day moving average price is $1.65. The company has a debt-to-equity ratio of 0.95, a quick ratio of 3.52 and a current ratio of 4.32. The stock has a market cap of $108.23 million, a P/E ratio of -2.17 and a beta of 0.33.
Pulmonx (NASDAQ:LUNG – Get Free Report) last posted its quarterly earnings data on Tuesday, October 27th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.07. Pulmonx had a negative return on equity of 96.66% and a negative net margin of 55.03%. The firm had revenue of $22.84 million during the quarter, compared to analyst estimates of $21.93 million. As a group, sell-side analysts expect that Pulmonx Corporation will post -1.05 earnings per share for the current fiscal year.
Insider Buying and Selling at Pulmonx
In other Pulmonx news, CEO Glendon French, III sold 41,882 shares of the business’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $2.26, for a total transaction of $94,653.32. Following the completion of the sale, the chief executive officer owned 1,137,936 shares of the company’s stock, valued at approximately $2,571,735.36. The trade was a 3.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel David Lehman sold 14,334 shares of the company’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $2.26, for a total value of $32,394.84. Following the completion of the sale, the general counsel owned 361,827 shares of the company’s stock, valued at approximately $817,729.02. The trade was a 3.81% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 78,340 shares of company stock valued at $177,048. Company insiders own 7.50% of the company’s stock.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the stock. Primecap Management Co. CA purchased a new stake in shares of Pulmonx in the second quarter worth $5,996,000. Almitas Capital LLC bought a new stake in shares of Pulmonx during the 2nd quarter valued at $1,383,000. BlackRock Inc. bought a new stake in shares of Pulmonx during the 2nd quarter valued at $1,147,000. Stonepine Capital Management LLC purchased a new position in shares of Pulmonx during the 2nd quarter valued at $1,060,067. Finally, Parkman Healthcare Partners LLC purchased a new position in shares of Pulmonx during the 2nd quarter valued at $841,000. 91.04% of the stock is owned by hedge funds and other institutional investors.
About Pulmonx
Pulmonx Corporation is a medical device company focused on developing minimally invasive treatments for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company’s technologies are designed to reduce hyperinflation in damaged portions of the lung and help improve breathing, exercise capacity and quality of life.
Pulmonx’s primary product is the Zephyr Endobronchial Valve, a bronchoscopically implanted, one-way valve intended for certain patients with severe emphysema.
Read More
- Five stocks we like better than Pulmonx
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Pulmonx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmonx and related companies with MarketBeat.com's FREE daily email newsletter.
